To examine the relevance of TP5 3 mutation in the treatment response to decitabine, the effects of decitabine on TP53 mutant (K052, NOMO-1)and TP53 wildtype (MV4-11, OCI-AML3) AML cell lines were evaluated. Decitabine showed preferential effects on TP53 mutated AML with increased ...
Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry ou...
近日,该公司宣布,美国食品和药物管理局(FDA)已授予APR-246联合阿扎胞苷(azacitidine)治疗携带一个易感TP53突变的骨髓增生异常综合征(MDS)的突破性药物资格(BTD)。之前,FDA还授予了APR-246治疗MDS的孤儿药资格(ODD)和快速通道资格(FTD);在欧盟,欧洲药品管理局(EMA)授予了APR-426治疗MDS、急性髓性白血病(AML)、卵巢...
9. Nannya Y, Takeda J, Sato S, et al. Molecular signatures that predict response to 阿扎胞苷citidine treatment for myelodysplastic syndromes. Vol. 130; 2017. 10. Sallman DA, Al Ali N, Yun S, et al. Clonal suppression of TP53 mutant MDS and oligoblastic AML with hypomethylating agent ...
In chronic lymphocytic leukemia (CLL), analysis of TP53 aberrations (deletion and/or mutation) is a crucial part of treatment decision-making algorithms. Technological and treatment advances have resulted in the need for an update of the last recommendat
本病例显示AML伴DDX41基因突变对经典化疗方案不敏感,预后差。DDX41基因位于5q35.3,是一种肿瘤抑制基因,由17个外显子组成,参与前体mRNA(pre-mRNA)剪接、RNA加工和核糖体合成 [ 1 ]。DDX41相关家族性骨髓增生异常综合征(myelodysplastic syndrome,MDS)及AML是一种常染色体显性疾病,通常见于中老年人群,由DEAD-box胚系...
急性髓系白血病(acute myeloid leukemia, AML)中,TP53基因异常与复杂核型(complex karyotype,CK)高度相关,70%的CK-AML存在TP53基因异常(突变和缺失分别占60%和40%),且TP53基因突变与老年、基因组复杂性、特定DNA拷贝数变异、单体核型以及不良预后相关。至少2/3...
原文出处:Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经...
4 The frequency of TP53 mutation is usually increased in the patients with advanced stages or aggressive types of cancers.5,6 Several studies have shown TP53 mutations are frequently detected in patients with therapy-related acute myeloid leukemia (AML)7 or AML with complex karyotype (AML-CK).8...
TP53 mutation status was also associated with MK, a feature that has frequently been cited as an independent prognostic measure in MDS and AML [7, 8, 11, 12, 31,32,33,34]. Eighty-eight percent of the TP53 mutant patients had MK compared to 61% without the mutation (p < 0.001)...